10x Genomics, Inc. ($TXG) Stock Forecast: Up 5.4% Today

What is 10x Genomics, Inc.?

10x Genomics Inc (TXG) is a gene sequencing technology provider listed on the NASDAQ. The company recently released its Q3 financial results, which did not meet expectations, resulting in a downturn in the market.

Why is 10x Genomics, Inc. going up?

TXG stock is up 5.4% on Oct 11, 2024 16:36

• TXG stock faced a decline after the Q3 sales results were below expectations, disappointing investors.
• The lackluster performance in Q3 may have raised concerns about the company's future growth and its ability to meet market forecasts.
• The decision by Ark Invest to sell off Moderna stock, despite positive post-COVID plans, likely added to a sense of caution in the biotech sector, impacting companies like 10x Genomics.
• In sum, the blend of TXG's financial results and the broader market dynamics probably contributed to the stock's downward movement today.

TXG Price Chart

TXG Technical Analysis

TXG News

Company News for Oct 11, 2024

Companies in The News Are: ...

https://www.zacks.com/stock/news/2349283/company-news-for-oct-11-2024

Cathie Wood's Ark Invest Dumps Over $9M In Moderna Stock - Even With Post-COVID Plans On The Table - ARK Genomic Revolution ETF ( BATS:ARKG ) , ARK Innovation ETF ( ARCA:ARKK )

On Thursday, Cathie Wood-led Ark Invest made a significant move by offloading shares of Moderna Inc MRNA. This decision comes amidst a backdrop of mixed analyst sentiments and Moderna's recently unveiled post-COVID roadmap.

https://www.benzinga.com/markets/equities/24/10/41284698/cathie-woods-ark-invest-dumps-over-9m-in-moderna-stock-even-with-post-covid-plans-on-the-table

Gene Sequencing Tech Provider 10x Genomics' Q3 Sales Fall Short On Expectations, But CEO Sees Opportunity Ahead - 10x Genomics ( NASDAQ:TXG )

10x Genomics Inc TXG stock is trading lower after the company, on Wednesday, released preliminary financial results for the third quarter of 2024, revealing a mixed performance.

https://www.benzinga.com/news/earnings/24/10/41268971/gene-sequencing-tech-provider-10x-genomics-q3-sales-fall-short-on-expectations-but-ceo-sees-opportu

Delta Air Lines, Domino's Pizza And 3 Stocks To Watch Heading Into Thursday - Delta Air Lines ( NYSE:DAL )

With U.S. stock futures trading lower this morning on Thursday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Delta Air Lines, Inc. DAL to report quarterly earnings at $1.52 per share on revenue of $14.67 billion before the opening bell, according to ...

https://www.benzinga.com/news/earnings/24/10/41265556/delta-air-lines-dominos-pizza-and-3-stocks-to-watch-heading-into-thursday

Trending Today

Fantom ($FTM) Crypto Forecast: Down 6.8% Today

Arbitrum ($ARB) Crypto Forecast: Down 5.9% Today

Hedera Hashgraph ($HBAR) Crypto Forecast: Down 5.2% Today

Render ($RENDER) Crypto Forecast: Down 5.6% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.5% Today

NEAR Protocol ($NEAR) Crypto Forecast: Down 5.1% Today

Solana ($SOL) Crypto Forecast: Down 5.1% Today

Aon plc Class A (UK) ($AON) Stock Forecast: Up 5.7% Today

Memecoin ($MEME) Crypto Forecast: Down 5.6% Today

Pendle ($PENDLE) Crypto Forecast: Down 6.0% Today

10x Genomics, Inc. Price History

11.09.2024 - TXG Stock was up 12.0%

• Despite Q3 sales underperforming, the CEO's positive outlook on future opportunities potentially boosted investor confidence in 10x Genomics' long-term growth.
• Speculations suggest that Ark Invest's shift away from Moderna Inc. may have prompted some investors to consider alternative biotech companies like 10x Genomics, influencing the stock's rise.
• The general bullish market sentiment included optimism towards firms with growth potential in genomic technology, increasing the demand for 10x Genomics shares.

11.09.2024 - TXG Stock was up 5.4%

• TXG stock faced a decline after the Q3 sales results were below expectations, disappointing investors.
• The lackluster performance in Q3 may have raised concerns about the company's future growth and its ability to meet market forecasts.
• The decision by Ark Invest to sell off Moderna stock, despite positive post-COVID plans, likely added to a sense of caution in the biotech sector, impacting companies like 10x Genomics.
• In sum, the blend of TXG's financial results and the broader market dynamics probably contributed to the stock's downward movement today.

27.07.2024 - TXG Stock was down 5.0%

• TXG's stock decline may be linked to the CEO and executive's share sales, potentially signaling doubts about the company's future performance and unsettling investors.
• The considerable share volumes offloaded by top management raise concerns about TXG's growth potential and forthcoming financial outcomes, fostering negative investor sentiment.
• While executives may sell company stock for personal financial reasons or diversification, these actions have likely contributed to the current downward pressure on TXG's stock price.

10.09.2024 - TXG Stock was down 27.1%

• TXG stock experienced a bearish movement as the company's Q3 sales fell short of expectations, indicating a potential lack of strong revenue growth.
• The CEO's optimistic outlook for future opportunities may have reassured investors, but the initial disappointment in the sales figures likely contributed to the downward pressure on the stock.
• The market may be reacting to the uncertainty surrounding 10x Genomics' financial performance, leading to a sell-off as investors reevaluate their positions in the company.

18.06.2024 - TXG Stock was down 6.9%

• The injunction impacting NanoString's CosMx Spatial Molecular Imager products in Germany, resulting from an ongoing patent dispute with 10x Genomics, potentially triggered concerns among investors, contributing to a pessimistic sentiment surrounding TXG.
• Despite optimistic price targets from Wall Street analysts pointing towards substantial upside potential, the stock registered a notable decline, suggesting possible market skepticism or uncertainty.
• The anticipated second-quarter 2024 financial results announcement could serve as a critical event influencing investor sentiment and adding to the volatility witnessed in TXG's stock price.
• The strong performance of Fulgent Genetics and the absence of significant strength in earnings estimate revisions for TXG likely factored into the bearish movement observed today.

23.06.2024 - TXG Stock was up 6.3%

• Significant trades by Cathie Wood's Ark Invest involving other companies like CrowdStrike and Tesla may have heightened investor interest in the tech and innovation sector, positively impacting companies like 10x Genomics (TXG).
• The recent announcement regarding the suspension of an injunction affecting NanoString's products related to an ongoing patent dispute with TXG could have reduced uncertainties surrounding TXG's legal challenges, potentially influencing the stock's upward movement.
• The consensus price target projecting an 85.7% upside potential for TXG, in addition to a positive trend in earnings estimate revisions, likely contributed to investor optimism and the strong bullish performance of the stock.

25.06.2024 - TXG Stock was up 5.6%

• Buying shares of Tesla despite recent challenges by a prominent investor could have signaled confidence in the EV sector, boosting overall market sentiment.
• The move to acquire shares of Tesla and CrowdStrike while selling off some Tesla stock might have led to a shift in investor focus towards innovative companies like 10x Genomics, contributing to its bullish movement.
• The positive sentiment around innovative tech companies like 10x Genomics, especially amidst turbulent market conditions, could have attracted more investors, driving the stock price higher.

13.07.2024 - TXG Stock was up 5.6%

• The uptrend in TXG stock today may be linked to a notable acquisition by Catherine Wood, boosting investor confidence in the company's future.
• Despite revising its 2024 guidance amid macro pressures, the market appears to view the company's adaptability positively.
• The recent appointment of Adam Taich as CFO could also be enhancing the optimistic outlook for TXG, suggesting potential strategic growth changes within the company.
• Positive sentiment towards gene editing stocks and the promise of medical advancements has likely contributed to the bullish momentum in 10x Genomics, with investors eyeing long-term growth opportunities in this sector.

09.07.2024 - TXG Stock was up 12.5%

• Positive earnings and revenue surprises in the recent financial report boosted TXG stock today.
• The company's adjustment in its 2024 guidance due to macro pressures was well-received by investors, showcasing its adaptability.
• The appointment of new CFO Adam Taich inspired confidence in the company's leadership and financial strategies.
• The optimistic outlook on gene editing stocks and market growth potential in the sector have fueled positive investor sentiment towards TXG.

07.07.2024 - TXG Stock was down 5.3%

• The bearish movement in TXG's stock today may be linked to negative earnings expectations, possibly leading to lower-than-expected earnings for the quarter.
• Market sentiment towards TXG could have been influenced by concerns over the company's performance in key metrics for the second quarter of 2024, contributing to downward pressure on the stock.
• Investors' reactions to the cautious outlook presented may be causing them to adjust their positions in TXG, reflecting the observed bearish movement in the market.

09.07.2024 - TXG Stock was up 7.3%

• The appointment of Adam Taich as the new CFO could have instilled confidence in investors, signaling potential positive strategic changes within the company.
• Despite reporting a loss in the second quarter, the fact that 10x Genomics topped revenue estimates could have reassured investors about the company's growth potential.
• The strong bullish movement in TXG's stock today might be attributed to the positive earnings surprise of 31.91% and revenue beat of 1.46% in the second quarter, indicating a strong performance and potential future growth.
• Wall Street estimates and projections for key metrics also likely played a role in boosting investor sentiment and driving the bullish movement in TXG's stock.

06.07.2024 - TXG Stock was up 5.7%

• The market movement of TXG today was likely influenced by the anticipation of its upcoming earnings report, which is expected to be negative. This could have resulted in a short-term surge in buying activity as investors may be speculating on potential future positive developments.